{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:15Z","timestamp":1786986915048,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.cld.2017.03.010","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:31:21Z","timestamp":1493080281000},"page":"555-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Dermatologic Manifestations of Chronic Hepatitis C Infection"],"prefix":"10.1016","volume":"21","author":[{"given":"Mehmet","family":"Sayiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Golabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freba","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2017.03.010_bib1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.010_bib2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/apt.13592","article-title":"Presence of hepatitis C (HCV) infection in baby boomers with Medicare is independently associated with mortality and resource utilisation","volume":"43","author":"Sayiner","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2017.03.010_bib3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.gtc.2015.07.006","article-title":"Extrahepatic manifestations of hepatitis C virus","volume":"44","author":"Vigano","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.cld.2017.03.010_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cgh.2006.06.010","article-title":"Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy","volume":"5","author":"Berk","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2017.03.010_bib5","first-page":"127","article-title":"Dermatologic extrahepatic manifestations of hepatitis C","volume":"3","author":"Dedania","year":"2015","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.cld.2017.03.010_bib6","first-page":"S78","article-title":"HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies","volume":"21","author":"Ferri","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cld.2017.03.010_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0272-6386(03)00412-8","article-title":"Monoclonal gammopathy: significance and possible causality in renal disease","volume":"42","author":"Paueksakon","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cld.2017.03.010_bib8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0002-9343(74)90852-3","article-title":"Biologic and clinical significance of cryoglobulins. A report of 86 cases","volume":"57","author":"Brouet","year":"1974","journal-title":"Am J Med"},{"key":"10.1016\/j.cld.2017.03.010_bib9","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/hep.21190","article-title":"Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C","volume":"43","author":"Saadoun","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.010_bib10","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","article-title":"A\u00a0role for hepatitis C virus infection in type II cryoglobulinemia","volume":"327","author":"Agnello","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2017.03.010_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-117-7-573","article-title":"Hepatitis C virus infection in patients with essential mixed cryoglobulinemia","volume":"117","author":"Misiani","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2017.03.010_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MD.0b013e3181c1750f","article-title":"Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection","volume":"88","author":"Matignon","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cld.2017.03.010_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2893.1998.00097.x","article-title":"Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia","volume":"5","author":"Donada","year":"1998","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2017.03.010_bib14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(11)60242-0","article-title":"The cryoglobulinaemias","volume":"379","author":"Ramos-Casals","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2017.03.010_bib15","first-page":"6518","article-title":"Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients","volume":"13","author":"Stefanova-Petrova","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2017.03.010_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1023\/B:MEBR.0000043982.17294.9b","article-title":"Hepatitis C virus-associated extrahepatic manifestations: a review","volume":"19","author":"Sene","year":"2004","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.cld.2017.03.010_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 5","key":"10.1016\/j.cld.2017.03.010_bib18","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"46","author":"Cacoub","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2017.03.010_bib19","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archderm.1995.01690220030006","article-title":"Essential mixed cryoglobulinemia. A comparative study of dermatologic manifestations in patients infected or noninfected with hepatitis C virus","volume":"131","author":"Dupin","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib20","first-page":"2199","article-title":"Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus","volume":"31","author":"Sene","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cld.2017.03.010_bib21","first-page":"101","article-title":"Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients","volume":"82","author":"Frankel","year":"1992","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.cld.2017.03.010_bib22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1600-0560.2007.00884.x","article-title":"The histological and pathogenetic spectrum of cutaneous disease in monoclonal gammopathies","volume":"35","author":"Rongioletti","year":"2008","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.cld.2017.03.010_bib23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.autrev.2011.01.008","article-title":"Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients","volume":"10","author":"Pietrogrande","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cld.2017.03.010_bib24","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","article-title":"Antiviral therapy for hepatitis C virus\u2013associated mixed cryoglobulinemia vasculitis: a long-term followup study","volume":"54","author":"Saadoun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.010_bib25","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.autrev.2015.05.013","article-title":"Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review","volume":"14","author":"Visentini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cld.2017.03.010_bib26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1601-0825.2010.01670.x","article-title":"Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis","volume":"16","author":"Lodi","year":"2010","journal-title":"Oral Dis"},{"key":"10.1016\/j.cld.2017.03.010_bib27","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/archdermatol.2009.200","article-title":"Hepatitis C virus and lichen planus: a reciprocal association determined by a meta-analysis","volume":"145","author":"Shengyuan","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMcp1103641","article-title":"Clinical practice. Lichen planus","volume":"366","author":"Le Cleach","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2017.03.010_bib29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1601-0825.2005.01142.x","article-title":"Number V oral lichen planus: clinical features and management","volume":"11","author":"Eisen","year":"2005","journal-title":"Oral Dis"},{"key":"10.1016\/j.cld.2017.03.010_bib30","first-page":"309","article-title":"Clinical variants of lichen planus","volume":"11","author":"Wagner","year":"2013","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.cld.2017.03.010_bib31","doi-asserted-by":"crossref","first-page":"742826","DOI":"10.1155\/2014\/742826","article-title":"Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis","volume":"2014","author":"Gorouhi","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.cld.2017.03.010_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0733-8635(02)00067-0","article-title":"The clinical manifestations and treatment of oral lichen planus","volume":"21","author":"Eisen","year":"2003","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.cld.2017.03.010_bib33","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1365-4632.2009.04062.x","article-title":"Lichen planus","volume":"48","author":"Lehman","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clindermatol.2009.03.004","article-title":"Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies","volume":"28","author":"Farhi","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib35","first-page":"237","article-title":"Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C","volume":"15","author":"Nagao","year":"2005","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.cld.2017.03.010_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/154411130301400205","article-title":"Oral diseases possibly associated with hepatitis C virus","volume":"14","author":"Carrozzo","year":"2003","journal-title":"Crit Rev Oral Biol Med"},{"key":"10.1016\/j.cld.2017.03.010_bib37","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1365-2133.2004.06257.x","article-title":"Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review","volume":"151","author":"Lodi","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib38","doi-asserted-by":"crossref","first-page":"615","DOI":"10.7326\/0003-4819-123-8-199510150-00008","article-title":"Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations","volume":"123","author":"Gumber","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2017.03.010_bib39","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/archderm.145.9.1048","article-title":"The relationship between lichen planus and hepatitis C clarified","volume":"145","author":"Bigby","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib40","first-page":"43","article-title":"Dermatologic manifestations of hepatitis C infection and the effect of interferon therapy: a literature review","volume":"15","author":"Jadali","year":"2012","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.cld.2017.03.010_bib41","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1742-1241.2004.00214.x","article-title":"Lichen planus and hepatitis C virus infection: an epidemiologic study","volume":"58","author":"Harman","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cld.2017.03.010_bib42","first-page":"53","article-title":"Diagnosis and treatment of lichen planus","volume":"84","author":"Usatine","year":"2011","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.cld.2017.03.010_bib43","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1600-0714.2008.00688.x","article-title":"Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations","volume":"38","author":"Carbone","year":"2009","journal-title":"J\u00a0Oral Pathol Med"},{"key":"10.1016\/j.cld.2017.03.010_bib44","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ajog.2004.02.061","article-title":"Patient satisfaction after the treatment of vulvovaginal erosive lichen planus with topical clobetasol and tacrolimus: a survey study","volume":"190","author":"Jensen","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.cld.2017.03.010_bib45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00000441-200303000-00006","article-title":"Extrahepatic manifestations of hepatitis C infection","volume":"325","author":"Mayo","year":"2003","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.cld.2017.03.010_bib46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10266-011-0008-3","article-title":"The magnitude of the association between hepatitis C virus infection and oral lichen planus: meta-analysis and case control study","volume":"99","author":"Petti","year":"2011","journal-title":"Odontology"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2017.03.010_bib47","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.33549\/physiolres.930000.55.S2.67","article-title":"European porphyria initiative (EPI): a platform to develop a common approach to the management of porphyrias and to promote research in the field","volume":"55","author":"Deybach","year":"2006","journal-title":"Physiol Res"},{"key":"10.1016\/j.cld.2017.03.010_bib48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-2005-923317","article-title":"Iron in nonhemochromatotic liver disorders","volume":"25","author":"Alla","year":"2005","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2017.03.010_bib49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510270142","article-title":"Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload","volume":"27","author":"Elder","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.010_bib50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1055\/s-2007-1007142","article-title":"Porphyria cutanea tarda","volume":"18","author":"Elder","year":"1998","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2017.03.010_bib51","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bpg.2010.08.010","article-title":"The acute hepatic porphyrias: current status and future challenges","volume":"24","author":"Siegesmund","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.cld.2017.03.010_bib52","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bpg.2010.07.002","article-title":"Porphyria cutanea tarda: when skin meets liver","volume":"24","author":"Frank","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.cld.2017.03.010_bib53","first-page":"188","article-title":"Porphyria cutanea tarda, hepatitis C, alcoholism, and hemochromatosis: a case report and review of the literature","volume":"73","author":"Sams","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.cld.2017.03.010_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.17219\/acem\/58955","article-title":"Clinical, biochemical and molecular characteristics of the main types of porphyria","volume":"25","author":"Szlendak","year":"2016","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.cld.2017.03.010_bib55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0308-2261(21)00178-8","article-title":"Cutaneous porphyria","volume":"9","author":"Magnus","year":"1980","journal-title":"Clin Haematol"},{"key":"10.1016\/j.cld.2017.03.010_bib56","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0168-8278(03)00346-5","article-title":"Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis","volume":"39","author":"Gisbert","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.010_bib57","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.4254\/wjh.v7.i27.2740","article-title":"Cutaneous manifestations of hepatitis C in the era of new antiviral agents","volume":"7","author":"Garcovich","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cld.2017.03.010_bib58","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.gastro.2007.10.011","article-title":"Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription","volume":"134","author":"Nishina","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2017.03.010_bib59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2230.2001.00825.x","article-title":"The management of porphyria cutanea tarda","volume":"26","author":"Sarkany","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.annder.2013.04.092","article-title":"Sclerodermatous changes in porphyria cutanea tarda: six cases","volume":"140","author":"Khayat","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.cld.2017.03.010_bib61","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","article-title":"Porphyrias","volume":"375","author":"Puy","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2017.03.010_bib62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.det.2014.03.001","article-title":"The cutaneous porphyrias","volume":"32","author":"Schulenburg-Brand","year":"2014","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.cld.2017.03.010_bib63","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/oxfordjournals.aje.a009745","article-title":"Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden","volume":"149","author":"Linet","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cld.2017.03.010_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-0560.1992.tb01557.x","article-title":"Histologic and immunofluorescence study of cutaneous porphyrias","volume":"19","author":"Maynard","year":"1992","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.cld.2017.03.010_bib65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/asheducation.V2012.1.19.3795678","article-title":"The porphyrias: advances in diagnosis and treatment","volume":"2012","author":"Balwani","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cld.2017.03.010_bib66","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/00365520310000672a","article-title":"Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C","volume":"38","author":"Fernandez","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2017.03.010_bib67","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10620-007-9945-7","article-title":"Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials","volume":"53","author":"Desai","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2017.03.010_bib68","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/bjd.13376","article-title":"Treatment of chronic hepatitis with boceprevir leads to remission of porphyria cutanea tarda","volume":"171","author":"Aguilera","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib69","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2017.03.010_bib70","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib71","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/archderm.132.11.1391","article-title":"Hepatitis C virus infection in patients with psoriasis","volume":"132","author":"Kanazawa","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib72","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2340\/0001555575482483","article-title":"Psoriasis and hepatitis C virus","volume":"75","author":"Yamamoto","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.cld.2017.03.010_bib73","article-title":"Hepatitis C may enhance key amplifiers of psoriasis","author":"Chun","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.cld.2017.03.010_bib74","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1468-3083.2012.04563.x","article-title":"Association between psoriasis and viral infections in the United States: focusing on hepatitis B, hepatitis C and human immunodeficiency virus","volume":"27","author":"Kanada","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.cld.2017.03.010_bib75","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jaad.2009.03.044","article-title":"Treatment of psoriasis in patients with hepatitis C: from the medical board of the National psoriasis foundation","volume":"61","author":"Frankel","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib76","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaad.2011.11.963","article-title":"Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection","volume":"67","author":"Raphael","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib77","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jaad.2005.04.049","article-title":"Necrolytic acral erythema: a cutaneous sign of hepatitis C virus infection","volume":"53","author":"Abdallah","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D32011024657","article-title":"Necrolytic acral erythema masquerading as cellulitis","volume":"20","author":"Iyengar","year":"2014","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.cld.2017.03.010_bib79","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jaad.2003.09.017","article-title":"Necrolytic acral erythema: response to combination therapy with interferon and ribavirin","volume":"50","author":"Hivnor","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cld.2017.03.010_bib80","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2340\/00015555-0186","article-title":"Cutaneous manifestations in patients positive for anti-hepatitis C virus antibodies","volume":"87","author":"Soylu","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.cld.2017.03.010_bib81","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamadermatol.2013.938","article-title":"Telaprevir-related dermatitis","volume":"149","author":"Roujeau","year":"2013","journal-title":"JAMA Dermatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326117300272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326117300272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T20:00:47Z","timestamp":1750190447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326117300272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1089326117300272"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2017.03.010","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic Manifestations of Chronic Hepatitis C Infection","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2017.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}